Eagle, long day and quick read and response. I believe AMRN gets another 3 years with expanded label. Obviously if there was a trial, that and all appeals would be complete by then, so I think the extra exclusivity makes it highly likely for a deal. (RI results were admitted by the judge in present case). I mean AMRN or whoever were to own them may get another indication in a couple of years and now there is another extension. I put settlement before a trial at 95%.
Eagle: My understanding is that a company can only obtain one 30 month stay per drug, so neither a broadened label nor additional patents in the orange book would give rise to a new 30 month stay.
News 
Market Data 
Discover 
